J B Chemicals and Pharmaceuticals Limited has announced significant changes in its senior management structure, disclosing the resignation of three key executives in March 2026. The pharmaceutical company communicated these developments to BSE Limited as part of its regulatory compliance obligations under SEBI listing requirements.

Senior Management Departures

The company reported the departure of three senior executives within a span of two days in March 2026:

Resignation Details

All three executives formally tendered their resignations in February 2026, with their last working days scheduled for early March. Mr. Kunal Khanna submitted his resignation as President-Operations on February 5, 2026, stating his commitment to ensuring seamless transition and cooperation during the handover period.

Mr. Dilip Singh Rathore also resigned on February 5, 2026, from his position as President (India Business), expressing gratitude for the support received and promising a smooth transition during the notice period. Mr. Jason D'souza submitted his resignation via email on February 6, 2026, from his role as Executive Vice President, indicating his intention to serve a three-month notice period while ensuring completion of his responsibilities.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication referenced SEBI Master Circulars bearing reference numbers SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and September 9, 2015.

Sandeep Phadnis, Vice President – Secretarial & Company Secretary, signed the formal communication to BSE Limited on March 10, 2026, requesting the exchange to take the resignations on record. The company provided copies of the resignation letters as supporting documentation for the regulatory filing.

Company Information

J.B. Chemicals & Pharmaceuticals Limited operates with its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra. The company maintains its commitment to pharmaceutical operations while managing this transition in senior leadership positions.

J B Chemicals and Pharmaceuticals Limited has announced the allotment of 31,160 equity shares under its Employee Stock Option Scheme (ESOP), marking another milestone in the company's employee incentive program. The pharmaceutical company disclosed this development to BSE Limited on February 19, 2026, in compliance with regulatory requirements.

ESOP Allotment Details

The Compensation Committee of the Board of Directors approved the allotment of 31,160 fully paid-up equity shares of Re. 1 each to one ESOP holder. The shares were allotted following the exercise of stock options granted under the JBCPL Employee Stock Option Scheme, 2021.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued, subscribed and paid-up capital. The share capital structure has been updated to reflect the new equity base following the ESOP exercise.

Regulatory Compliance

The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulations, 2015. The communication was sent to BSE Limited, where the company's shares are listed under scrip code 506943 and stock symbol JBCHEPHARM. The disclosure also references the SEBI Master Circular bearing reference number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Information

J.B. Chemicals & Pharmaceuticals Limited operates with its registered office in Ahmedabad, Gujarat, and corporate office in Mumbai, Maharashtra. The company, incorporated with CIN L24390GJ1976PLC173077, continues to execute its employee stock option schemes as part of its human resource strategy. The allotment was communicated by Sandeep Phadnis, Vice President – Secretarial & Company Secretary, ensuring proper regulatory compliance and transparency.